Expression of molecular markers predict breast cancer to neoadjuvant anthracycline chemotherapy value           CHEN Yi-zuo*, CHEN Can-ming, FEI Fei, et al.  *Department of Breast Surgery, Fudan University Shanghai Cancer Center,Shanghai 200032, China
Corresponding author: WU Jiong, E-mail：wujiong1122@vip.sina.com
Abstract    Objective    To investigate the predictive value of biological markers for responsiveness to anthracyline-based regimen in neoadjuvant systemic therapy for local advanced breast caner. Methods    Postoperative paraffin-embedded tumor samples from 420 breast cancer patients admitted between January 2000 and December 2010 in Department of Breast Surgery of Fudan University Shanghai Cancer Center were examined for expression of ER, PR, Her-2/neu and other 15 markers by immunohistochemistry, to analyze the predictive value of the biological markers for response to neoadjuvant chemotherapy. Results    Negative p53, cathepsin-D and loss of GSTπwere significantly predictive for an effective response to anthracycline-based neoadjuvant chemotherapy. In multivariate logistic regression analysis, the GSTπand p53 status were found with independent predictive value. Conclusion    Loss of GSTπand p53  independently predict the response to anthracycline-based regimen.